B-type natriuretic peptide-guided therapy for heart failure (HF): a systematic review and meta-analysis of individual participant data (IPD) and aggregate data

[1]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[2]  J. Higgins,et al.  Effectiveness and cost-effectiveness of serum B-type natriuretic peptide testing and monitoring in patients with heart failure in primary and secondary care: an evidence synthesis, cohort study and cost-effectiveness model. , 2017, Health technology assessment.

[3]  S. Purdy,et al.  The healthcare costs of heart failure during the last five years of life: A retrospective cohort study , 2016, International journal of cardiology.

[4]  P. Kirchhof,et al.  Effect of age and sex on efficacy and tolerability of β blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis , 2016, British Medical Journal.

[5]  T. Schilling,et al.  Auswirkung einer leitliniengerechten Behandlung auf die Mortalität bei Linksherzinsuffizienz , 2016, Herz.

[6]  P. Johansson,et al.  Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study , 2016, BMC Cardiovascular Disorders.

[7]  A. Haverich,et al.  [Impact of guideline adherence on mortality in treatment of left heart failure]. , 2016, Herz.

[8]  M. Pfisterer,et al.  Which heart failure patients profit from natriuretic peptide guided therapy? A meta‐analysis from individual patient data of randomized trials , 2015, European journal of heart failure.

[9]  David Fisher,et al.  Two-stage Individual Participant Data Meta-analysis and Generalized Forest Plots , 2015 .

[10]  P. Collinson,et al.  Effects of nebivolol on biomarkers in elderly patients with heart failure. , 2014, International journal of cardiology.

[11]  J. Higgins,et al.  Protocol for a systematic review and individual participant data meta-analysis of B-type natriuretic peptide-guided therapy for heart failure , 2014, Systematic Reviews.

[12]  C. O'connor,et al.  Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis , 2014, European heart journal.

[13]  R. De Vecchis,et al.  B-type natriuretic peptide-guided versus symptom-guided therapy in outpatients with chronic heart failure: a systematic review with meta-analysis , 2014, Journal of cardiovascular medicine.

[14]  M. Nangaku,et al.  Successful treatment of acute kidney injury in patients with idiopathic nephrotic syndrome using human atrial natriuretic Peptide. , 2014, Internal medicine.

[15]  S. Mi,et al.  Does B-type natriuretic peptide-guided therapy improve outcomes in patients with chronic heart failure? A systematic review and meta-analysis of randomized controlled trials , 2014, Heart Failure Reviews.

[16]  P. Erne,et al.  N‐terminal pro brain natriuretic peptide‐guided management in patients with heart failure and preserved ejection fraction: findings from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME‐CHF) , 2013, European journal of heart failure.

[17]  Yi-Ming Chen,et al.  B-type natriuretic peptide-guided chronic heart failure therapy: a meta-analysis of 11 randomised controlled trials. , 2013, Heart, lung & circulation.

[18]  Abhinav Sharma,et al.  Similarities and Differences in Patient Characteristics Between Heart Failure Registries Versus Clinical Trials , 2013, Current Heart Failure Reports.

[19]  J. Parissis,et al.  Guiding decongestion treatment in chronic heart failure patients. Clinical assessment or serial laboratory evaluation , 2013 .

[20]  P. Hildebrandt,et al.  Adding serial N‐terminal pro brain natriuretic peptide measurements to optimal clinical management in outpatients with systolic heart failure: a multicentre randomized clinical trial (NorthStar monitoring study) , 2013, European journal of heart failure.

[21]  D. Leosco,et al.  Natriuretic Peptide-Guided Therapy in Chronic Heart Failure: A Meta-Analysis of 2,686 Patients in 12 Randomized Trials , 2013, PloS one.

[22]  A. Sutton,et al.  Assessment of publication bias, selection bias, and unavailable data in meta-analyses using individual participant data: a database survey , 2012, BMJ : British Medical Journal.

[23]  Shawn A. Gregory,et al.  Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction. , 2011, Journal of the American College of Cardiology.

[24]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[25]  U. Dahlström,et al.  Brain natriuretic peptide‐guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome , 2011, European journal of heart failure.

[26]  D. Blondheim,et al.  NT-proBNP-Guided Preemptive Treatment of Outpatients With Chronic Heart Failure Followed in a out Hospital Clinic , 2011 .

[27]  R. Califf,et al.  The STARBRITE trial: a randomized, pilot study of B-type natriuretic peptide-guided therapy in patients with advanced heart failure. , 2011, Journal of cardiac failure.

[28]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[29]  M. Prins,et al.  Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. , 2010, Journal of the American College of Cardiology.

[30]  K. Swedberg,et al.  Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT‐proBNP Guided Management of Heart Failure – SIGNAL‐HF (Swedish Intervention study – Guidelines and NT‐proBNP AnaLysis in Heart Failure) , 2010, European journal of heart failure.

[31]  Amador López-Granados,et al.  Utilidad de los valores del péptido natriurético cerebral frente al control clínico habitual para la monitorización del tratamiento en pacientes con insuficiencia cardiaca , 2010 .

[32]  B. Billah,et al.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis. , 2010, Archives of internal medicine.

[33]  D. Moertl,et al.  N-terminal pro-B-type natriuretic peptide-guided, intensive patient management in addition to multidisciplinary care in chronic heart failure a 3-arm, prospective, randomized pilot study. , 2010, Journal of the American College of Cardiology.

[34]  J. Suárez de Lezo,et al.  [Usefulness of brain natriuretic peptide levels, as compared with usual clinical control, for the treatment monitoring of patients with heart failure]. , 2010, Medicina clinica.

[35]  C. Frampton,et al.  N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. , 2009, Journal of the American College of Cardiology.

[36]  V. Hasselblad,et al.  Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. , 2009, American heart journal.

[37]  Peter Buser,et al.  BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. , 2009, JAMA.

[38]  A. Cohen-Solal,et al.  Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. , 2007, Journal of the American College of Cardiology.

[39]  Simon G Thompson,et al.  Can meta-analysis help target interventions at individuals most likely to benefit? , 2005, The Lancet.

[40]  Jonathan A C Sterne,et al.  Funnel Plots in Meta-analysis , 2004 .

[41]  Lesley A Stewart,et al.  PUBLICATION BIAS AND META-ANALYSES , 2003, International Journal of Technology Assessment in Health Care.

[42]  J. Cohn,et al.  A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. , 2001, The New England journal of medicine.

[43]  A Whitehead,et al.  Meta‐analysis of continuous outcome data from individual patients , 2001, Statistics in medicine.

[44]  C. Frampton,et al.  Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations , 2000, The Lancet.

[45]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[46]  Salim Yusuf,et al.  Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. , 1991, The New England journal of medicine.

[47]  K. Swedberg,et al.  Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). , 1988, The American journal of cardiology.